MET and prostate cancer: Genetic contributions to prostate cancer have been well documented, including loss of tumor suppressors such as PTEN and p53, and activation of oncogenes like SRC, MET, and FGFR but many of the molecular drivers of aggressive prostate cancer remain elusive2.